Aduro Clean Technologies gibt Abschluss des Uplistings in Höhe von 4 Mio. USD an der Nasdaq bekannt
November 09, 2024 15:41 ET
|
Aduro Clean Technologies Inc.
LONDON, Ontario, Nov. 09, 2024 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. („Aduro“ oder das „Unternehmen“) (Nasdaq: ADUR) (CSE: ACT) (FSE: 9D5), ein Unternehmen für saubere Technologien, das...
Aduro Clean Technologies annonce la clôture de sa cotation au Nasdaq pour un montant de 4 millions de dollars
November 09, 2024 15:41 ET
|
Aduro Clean Technologies Inc.
LONDON, Province de l’Ontario, 09 nov. 2024 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc., ci-après « Aduro » ou la « Société » (Nasdaq : ADUR) (CSE : ACT) (FSE : 9D5), une société de...
Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer
November 09, 2024 13:40 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., Nov. 09, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new data highlighting the potential of...
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
November 09, 2024 13:30 ET
|
Fate Therapeutics, Inc.
Novel H2CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on Tumor Cells in Preclinical Studies Initial Low-Dose Cohort of FT825 / ONO-8250 as Monotherapy Shows...
Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)
November 09, 2024 13:00 ET
|
Replimune Group Inc
Oral presentation highlighting IGNYTE primary analysis data shows anti-tumor activity across all subgroups with injected and non-injected lesions responding with similar frequency, depth, duration,...
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit
November 09, 2024 10:30 ET
|
Ultragenyx Pharmaceutical Inc.
Phase 1/2 data show improvements across all domains and confirm that Phase 3 Aspire study is amply powered to establish efficacy of GTX-102 Phase 3 program on track to begin enrollment by...
Mission Produce® Implements Policy Addressing Illegal Deforestation
November 08, 2024 20:00 ET
|
Mission Produce, Inc.
OXNARD, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Mission Produce, Inc. (NASDAQ: AVO) (“Mission” or “the Company”) a world leader in sourcing, producing, and distributing fresh Hass avocados, today...
AppLovin Corporation to Join the Nasdaq-100 Index® Beginning November 18, 2024
November 08, 2024 20:00 ET
|
Nasdaq, Inc.
NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced that AppLovin Corporation (Nasdaq: APP), will become a component of the Nasdaq-100 Index® (Nasdaq: NDX®) and the...
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 08, 2024 17:30 ET
|
InspireMD, Inc.
MIAMI, Nov. 08, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation...
Prestige Wealth Inc. Announces Acquisitions of InnoSphere Tech and Closing of Acquisition of Wealth AI
November 08, 2024 17:00 ET
|
Prestige Wealth Inc.
HONG KONG, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Prestige Wealth Inc. (NASDAQ: PWM) (“PWM”, or the “Company”), a wealth management and asset management services provider based in Hong Kong, today...